An international group of investigators, including Dr. Mansoor Saleh, principal investigator and Director of Clinical Research at Georgia Cancer Specialists (GCS), recently published findings of a pivotal trial of the new prostate cancer therapy Abiraterone in the New England Journal of Medicine.
The results of a randomized clinical trial involving patients with metastatic prostate cancer who had previously received chemotherapy, “Abiraterone and Increased Survival in Metastatic Prostate Cancer,” was published on May 26, 2011. The article demonstrated that Abiraterone plus prednisone increased overall survival time, as compared to the placebo plus prednisone group.
“This international trial accrued 1,195 patients, and GCS was one of the leading sites for this trial in the United States,” Dr. Saleh said. “It’s quite an achievement to have a community-based private practice group achieve authorship in the New England Journal of Medicine, and I’m extremely proud of the great work on the part of our practice’s physicians and strong research team.”
Georgia Cancer Specialists is a Top 10 private cancer practice in the U.S. and a leader in advanced cancer treatment and research. The practice supports more than 200,000 patient visits each year. GCS offers community-based medical oncology and hematology services and is the first private oncology practice to also provide a full range of support services for patients in Georgia, including nutritional counseling, pain management, wellness counseling, and home health coordination. The GCS research department, whose focus is bringing targeted cancer therapy to communities, is the first in Georgia to offer Phase I clinical trials, the most novel cancer therapies available. GCS has 31 offices, 45 physicians, and more than 500 support staff members located in Metro Atlanta, North and Central Georgia, Southeast Tennessee, and Southwest North Carolina. Georgia Cancer Specialists can be found on the web at www.gacancer.com. GCS is The Cancer Answer.
Loading map...
